Care of the Elderly Resources

Search Knowledge Base by Keyword

Additional Resources

You are here:
< Back

Journal Articles:

  1. Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G. MDS research criteria for prodromal Parkinson’s disease. Mov Disord. 2015 Oct;30(12):1600-11. PubMed PMID: 26474317.
  2. Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna). 2003 May;110(5):517-36. Review. PubMed PMID: 12721813.
  3. Broen MP, Braaksma MM, Patijn J, Weber WE. Prevalence of pain in Parkinson’s disease: a systematic review using the modified QUADAS toolMov Disord. 2012;27(4):480-484. doi:10.1002/mds.24054
  4. Chung CL, Thilarajah S, Tan D. Effectiveness of resistance training on muscle strength and physical function in people with Parkinson’s disease: a systematic review and meta-analysis. Clin Rehabil. 2016 Jan;30(1):11-23.
  5. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014 Apr 23-30;311(16):1670-83. doi: 10.1001/jama.2014.3654. Review. PubMed PMID: 24756517.
  6. Deuschl G, Agid Y. Subthalamic neurostimulation for Parkinson’s disease with early fluctuations: balancing the risks and benefitsLancet Neurol. 2013;12(10):1025-1034. doi:10.1016/S1474-4422(13)70151-0
  7. Fahn S, Poewe W. Levodopa: 50 years of a revolutionary drug for Parkinson diseaseMov Disord. 2015;30(1):1-3. doi:10.1002/mds.26122
  8. Goetz CG, Pal G. Initial management of Parkinson’s disease. BMJ. 2014 Dec 19;349:g6258. doi: 10.1136/bmj.g6258. Review. PubMed PMID: 25527341.
  9. Kalia LV, Kalia SK, Lang AE. Disease-modifying strategies for Parkinson’s disease. Mov Disord. 2015 Sep 15;30(11):1442-50. doi: 10.1002/mds.26354. Epub 2015 Jul 24. Review. PubMed PMID: 26208210.
  10. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015 Aug 29;386(9996):896-912. doi: 10.1016/S0140-6736(14)61393-3. Epub 2015 Apr 19. Review. PubMed PMID: 25904081.
  11. Lertxundi U, Peral J, Mora O, Domingo-Echaburu S, Martínez-Bengoechea MJ, García-Moncó JC. Antidopaminergic therapy for managing comorbidities in patients with Parkinson’s disease. Am J Health Syst Pharm. 2008;65(5):414-419. doi:10.2146/ajhp060624
  12. Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol. 2014 Apr;71(4):499-504. doi: 10.1001/jamaneurol.2013.6233. Review. PubMed PMID: 24514863.


Online Resources:

  1. Parkinson’s Society of Canada:
  2. Unified Parkinson’s Disease Rating Scale System:
  4. Davis Phinney Foundation:
  5. Parkinson’s Clinical Guidelines:
  6. University Health Network (UHN) – Feeding Choices for People with Advanced Parkinson’s Disease: